Ocera Therapeutics Company Profile (NASDAQ:OCRX)

About Ocera Therapeutics

Ocera Therapeutics logoOcera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: OCRX
  • CUSIP:
Key Metrics:
  • Previous Close: $2.64
  • 50 Day Moving Average: $2.40
  • 200 Day Moving Average: $2.63
  • 52-Week Range: $21,851,000.00 - $1.76
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.05
  • P/E Growth: 0.00
  • Market Cap: $57.69M
  • Outstanding Shares: 21,851,000
  • Beta: 2.28
Profitability:
  • Net Margins: -23,955.08%
  • Return on Equity: -97.93%
  • Return on Assets: -66.32%
Debt:
  • Debt-to-Equity Ratio: 0.39%
  • Current Ratio: 6.00%
  • Quick Ratio: 6.00%
Additional Links:
Companies Related to Ocera Therapeutics:

Analyst Ratings

Consensus Ratings for Ocera Therapeutics (NASDAQ:OCRX) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.50 (297.73% upside)
Analysts' Ratings History for Ocera Therapeutics (NASDAQ:OCRX)
Show:
DateFirmActionRatingPrice TargetDetails
9/22/2016JMP SecuritiesReiterated RatingBuyView Rating Details
4/12/2016Brean CapitalReiterated RatingBuyView Rating Details
3/6/2016Cowen and CompanyReiterated RatingBuy$11.00View Rating Details
3/12/2015Stifel NicolausLower Price TargetBuy$17.00 -> $15.00View Rating Details
(Data available from 9/26/2014 forward)

Earnings

Earnings History for Ocera Therapeutics (NASDAQ:OCRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2016        
8/3/2016Q2($0.35)($0.33)ViewN/AView Earnings Details
4/29/2016Q1($0.33)($0.36)ViewN/AView Earnings Details
3/3/2016Q415($0.33)($0.34)ViewN/AView Earnings Details
8/3/2015Q215($0.40)($0.46)ViewN/AView Earnings Details
4/30/2015Q115($0.29)($0.34)ViewN/AView Earnings Details
3/11/2015Q414($0.46)($0.28)ViewN/AView Earnings Details
11/13/2014Q314($0.50)($0.34)ViewN/AView Earnings Details
8/11/2014Q114($0.45)($0.46)ViewN/AView Earnings Details
5/8/2014($0.43)($0.27)ViewN/AView Earnings Details
3/13/2014Q413($0.21)($0.48)$2.93 million$52.00 millionViewN/AView Earnings Details
11/13/2013Q3 13($0.77)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ocera Therapeutics (NASDAQ:OCRX)
Current Year EPS Consensus Estimate: $-1.34 EPS
Next Year EPS Consensus Estimate: $-1.29 EPS

Dividends

Dividend History for Ocera Therapeutics (NASDAQ:OCRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ocera Therapeutics (NASDAQ:OCRX)
Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 36.03%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/4/2016Linda S GraisCEOBuy3,000$3.19$9,570.00View SEC Filing  
1/22/2016Linda S GraisCEOBuy10,000$2.38$23,800.00View SEC Filing  
1/15/2016Gaurav AggarwalInsiderBuy10,000$2.15$21,500.00View SEC Filing  
1/15/2016Michael ByrnesCFOBuy3,500$2.07$7,245.00View SEC Filing  
6/23/2015Wendall WierengaDirectorBuy5,000$3.71$18,550.00View SEC Filing  
5/7/2015Rajiv PatniInsiderBuy5,050$3.97$20,048.50View SEC Filing  
5/6/2015Gaurav AggarwalInsiderBuy7,500$3.62$27,150.00View SEC Filing  
5/6/2015Linda S GraisCEOBuy30,000$3.73$111,900.00View SEC Filing  
5/6/2015Michael ByrnesCFOBuy2,500$3.61$9,025.00View SEC Filing  
10/1/2014Michael ByrnesVPBuy2,000$4.81$9,620.00View SEC Filing  
7/11/2014Linda S GraisCEOBuy10,000$5.93$59,300.00View SEC Filing  
7/11/2014Sharon TetlowCFOBuy3,000$5.83$17,490.00View SEC Filing  
7/15/2013Brian K HalakMajor ShareholderBuy995,618$6.03$6,003,576.54View SEC Filing  
7/15/2013Michael PowellDirectorBuy391,166$6.03$2,358,730.98View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ocera Therapeutics (NASDAQ:OCRX)
DateHeadline
News IconTrading the Biotech News: Ocera Therapeutics, Inc. (NASDAQ:OCRX), Amicus Therapeutics, Inc. (NASDAQ:FOLD) - The Voice Registrar (NASDAQ:OCRX)
voiceregistrar.com - September 25 at 5:51 PM
News IconUnder the Microscope, Zeroing in at Ocera Therapeutics, Inc. (NASDAQ:OCRX) - Duncan Research (NASDAQ:OCRX)
www.duncanindependent.com - September 23 at 6:05 PM
streetinsider.com logoOcera Therapeutics (OCRX) Completes Enrollment in Phase 2a Study of OCR-002 to Treat Acute Liver Failure - StreetInsider.com (NASDAQ:OCRX)
www.streetinsider.com - September 23 at 6:05 PM
News IconTop Biotechnology Stock Picking: Vitae Pharmaceuticals, Inc. (VTAE), Ocera Therapeutics, Inc. (OCRX) - The Independent Republic (NASDAQ:OCRX)
theindependentrepublic.com - September 23 at 6:05 PM
News IconKeen Investors Find News on Ocera Therapeutics, Inc. (NASDAQ:OCRX) - Duncan Research (NASDAQ:OCRX)
www.duncanindependent.com - September 23 at 6:05 PM
streetinsider.com logoOcera Therapeutics (OCRX) Completes Enrollment in Phase 2a Study of OCR-002 to Treat Acute Liver Failure (NASDAQ:OCRX)
www.streetinsider.com - September 22 at 11:22 AM
globenewswire.com logoOcera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver Failure (NASDAQ:OCRX)
globenewswire.com - September 21 at 6:10 PM
finance.yahoo.com logoOcera to Present at the Ladenburg Thalmann 2nd Annual Healthcare Conference (NASDAQ:OCRX)
finance.yahoo.com - September 20 at 11:49 AM
biz.yahoo.com logoOCERA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:OCRX)
biz.yahoo.com - September 19 at 11:03 AM
publicnow.com logoOcera Initiates Phase 1 Clinical Study of Orally Available OCR-002 in Patients with Cirrhosis for the Prevention of Hepatic Encephalopathy (NASDAQ:OCRX)
www.publicnow.com - September 19 at 11:03 AM
biz.yahoo.com logoOCERA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:OCRX)
biz.yahoo.com - September 15 at 6:36 PM
publicnow.com logoOcera Announces Management Transition (NASDAQ:OCRX)
www.publicnow.com - September 15 at 6:36 PM
finance.yahoo.com logoOcera Therapeutics (OCRX) Sees Hammer Chart Pattern: Time to Buy? (NASDAQ:OCRX)
finance.yahoo.com - September 12 at 11:07 AM
capitalcube.com logoETF’s with exposure to Ocera Therapeutics, Inc. : September 1, 2016 (NASDAQ:OCRX)
www.capitalcube.com - September 1 at 6:31 PM
capitalcube.com logoOcera Therapeutics, Inc. :OCRX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016 (NASDAQ:OCRX)
www.capitalcube.com - August 9 at 6:52 PM
biz.yahoo.com logoOCERA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:OCRX)
biz.yahoo.com - August 4 at 7:00 PM
twst.com logoOcera Therapeutics Inc.: Ocera Therapeutics Reports Second Quarter 2016 Financial Results and Company Update (NASDAQ:OCRX)
www.twst.com - August 4 at 9:45 AM
biz.yahoo.com logoOCERA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and (NASDAQ:OCRX)
biz.yahoo.com - August 3 at 6:56 PM
publicnow.com logoOcera Therapeutics Reports Second Quarter 2016 Financial Results and Company Update (NASDAQ:OCRX)
www.publicnow.com - August 3 at 6:56 PM
capitalcube.com logoETF’s with exposure to Ocera Therapeutics, Inc. : July 5, 2016 (NASDAQ:OCRX)
www.capitalcube.com - July 5 at 1:08 PM
News IconOcera Therapeutics Incorporated (NASDAQ:OCRX) Sellers Covered 21.23% of Their Shorts - Engelwood Daily (NASDAQ:OCRX)
www.engelwooddaily.com - June 28 at 11:27 AM
ftsenews.co.uk logoNew Broker Ratings For Ocera Therapeutics, Inc. (OCRX) - FTSE News (NASDAQ:OCRX)
www.ftsenews.co.uk - June 24 at 9:12 AM
News IconOcera Therapeutics Incorporated (NASDAQ:OCRX) Shorted Shares Decreased By 10.26% - Engelwood Daily (NASDAQ:OCRX)
www.engelwooddaily.com - June 24 at 9:12 AM
fiscalstandard.com logoBrokers Issue Average Price Target Of 17.00 On Ocera Therapeutics, Inc. (OCRX) - Fiscal Standard (NASDAQ:OCRX)
www.fiscalstandard.com - June 24 at 9:12 AM
biz.yahoo.com logoOCERA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure (NASDAQ:OCRX)
biz.yahoo.com - June 21 at 4:07 PM
fiscalstandard.com logoThis Weeks Broker Views For Ocera Therapeutics, Inc. (OCRX) - Fiscal Standard (NASDAQ:OCRX)
www.fiscalstandard.com - June 20 at 8:13 AM
biz.yahoo.com logoOCERA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vo (NASDAQ:OCRX)
biz.yahoo.com - June 15 at 5:30 PM
publicnow.com logoOcera to Present at the JMP Securities Life Sciences Conference (NASDAQ:OCRX)
www.publicnow.com - June 13 at 4:29 PM
capitalcube.com logoETF’s with exposure to Ocera Therapeutics, Inc. : June 8, 2016 (NASDAQ:OCRX)
www.capitalcube.com - June 8 at 2:25 PM
capitalcube.com logoOcera Therapeutics, Inc. :OCRX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 7, 2016 (NASDAQ:OCRX)
www.capitalcube.com - June 7 at 11:07 AM
publicnow.com logoOcera to Present at the Jefferies 2016 Healthcare Conference (NASDAQ:OCRX)
www.publicnow.com - May 31 at 4:43 PM
publicnow.com logoOcera to Present at the 2016 BIO International Convention (NASDAQ:OCRX)
www.publicnow.com - May 26 at 4:17 PM
streetupdates.com logoStocks Movements to Focus: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) , Ocera Therapeutics, Inc. (NASDAQ ... - Street Updates (NASDAQ:OCRX)
www.streetupdates.com - May 20 at 2:38 PM
News IconThis Weeks Broker Price Targets For Ocera Therapeutics, Inc. (OCRX) - Share Trading News (NASDAQ:OCRX)
www.sharetrading.news - May 3 at 8:16 AM
realistinvestor.com logoOcera Therapeutics, Inc. (NASDAQ:OCRX) Boasts An Average Rating Of 2 - RealistInvestor.com (NASDAQ:OCRX)
www.realistinvestor.com - May 2 at 8:43 AM
rttnews.com logoACAD Gets FDA Nod, High-Five For ABBV's Imbruvica, NLNK Waits To Impress (NASDAQ:OCRX)
www.rttnews.com - May 2 at 8:43 AM
News IconLatest Analyst Ratings For Ocera Therapeutics, Inc. (OCRX) - Share Trading News (NASDAQ:OCRX)
www.sharetrading.news - April 30 at 8:38 AM
twst.com logoOcera Therapeutics Inc.: Ocera Therapeutics Reports First Quarter 2016 Financial Results and Pipeline Progress (NASDAQ:OCRX)
www.twst.com - April 30 at 8:38 AM
finance.yahoo.com logoOcera Therapeutics Reports First Quarter 2016 Financial Results and Pipeline Progress (NASDAQ:OCRX)
finance.yahoo.com - April 29 at 9:05 AM
News IconOcera Therapeutics, Inc. (OCRX) Latest Broker Views - Risers & Fallers (NASDAQ:OCRX)
www.risersandfallers.com - April 25 at 9:24 AM
News IconAnalyst Coverage: Ocera Therapeutics, Inc. (OCRX) - Risers & Fallers (NASDAQ:OCRX)
www.risersandfallers.com - April 23 at 8:58 AM
News IconOcera Therapeutics, Inc. (OCRX) Updated Broker Price Targets - Share Trading News (NASDAQ:OCRX)
www.sharetrading.news - April 20 at 10:07 AM
seekingalpha.com logoOcera Therapeutics: A Speculative Investment - Seeking Alpha (NASDAQ:OCRX)
seekingalpha.com - April 20 at 10:07 AM
streetinsider.com logoOcera Therapeutics (OCRX) Will Present Preclinical Data from Two OCR-002 Studies at EASL - StreetInsider.com (NASDAQ:OCRX)
www.streetinsider.com - April 15 at 12:41 PM
benzinga.com logoOcera Therapeutics Reports Presentation of Two Preclinical Studies Showing Further Support for OCR-002 (NASDAQ:OCRX)
www.benzinga.com - April 15 at 12:41 PM
nasdaq.com logoOcera Therapeutics Announces Presentation of Two Preclinical Studies Further Supporting Its Ammonia (NASDAQ:OCRX)
www.nasdaq.com - April 15 at 12:41 PM
publicnow.com logoOcera Therapeutics Announces Presentation of Two Preclinical Studies Further Supporting Its Ammonia Scavenger OCR-002 at The International Liver Congress™ 2016 of the European Association for the Study of the Liver (EASL) (NASDAQ:OCRX)
www.publicnow.com - April 15 at 9:13 AM
finance.yahoo.com logo9:08 am Ocera Therapeutics announces presentation of 2 pre-clinical studies 'further supporting' its ammonia scavenger OCR-002 at the International Liver Congress 2016 of the European Association for the study of the liver (NASDAQ:OCRX)
finance.yahoo.com - April 15 at 9:08 AM
News IconOcera Therapeutics Inc (OCRX) Earns Buy Rating from Brean Capital - Washington News Wire (NASDAQ:OCRX)
washingtonnewswire.com - April 14 at 2:04 PM
News IconCurrent Price Targets For Ocera Therapeutics, Inc. (OCRX) - Risers & Fallers (NASDAQ:OCRX)
www.risersandfallers.com - April 13 at 2:42 PM

Social

Ocera Therapeutics (NASDAQ:OCRX) Chart for Monday, September, 26, 2016


Last Updated on 9/26/2016 by MarketBeat.com Staff